Table 1. Baseline characteristics of the study cohort (n=134).
| Variables | Median | Range or No. (%) |
|---|---|---|
| Age (yr) | 47 | 17–76 |
| CA-125 level before secondary cytoreduction (U/mL) | 186.2 | 3.2–3,240.0 |
| Median interval between primary treatment and secondary cytoreduction (mo) | 38.2 | 7.1–136.6 |
| Overall survival after secondary cytoreduction (mo) | 39.1 | 2.1–126.1 |
| Stage at initial diagnosis | I | 18 (13.5) |
| II | 11 (8.2) | |
| III | 86 (64.1) | |
| IV | 19 (14.2) | |
| Histologic type | Papillary serous carcinoma | 86 (64.1) |
| Endometrioid adenocarcinoma | 17 (12.7) | |
| Mucinous adenocarcinoma | 9 (6.7) | |
| Clear cell carcinoma | 8 (6.0) | |
| Others | 14 (10.5) | |
| Result of secondary cytoreduction | Residual tumor (−) | 90 (67.2) |
| Residual tumor (+) | 34 (25.4) | |
| No recurrence | 10 (7.5) | |
| Final status of patients | Complete remission | 23 (17.2) |
| Alive with disease | 23 (17.2) | |
| Died of disease | 88 (65.7) |
CA-125, cancer antigen 125.